In the post-launch phase, Xcenda recommends manufacturers conduct retrospective or prospective studies to understand the real-world impact of their product. Such studies can uncover new evidence to strengthen or refine the product's clinical and economic value proposition. And consistent research with payers and providers will forecast how policy changes or the availability of new, competitive therapies could impact coverage and utilization.

Maximize commercial opportunities with the following key services:

Build an outcomes analyzer

Give payers a user-friendly software tool to understand patient treatment patterns, identify at-risk populations, and/or analyze healthcare resource consumption within their own patient population.

Read More

Develop quality improvement programs

For high-cost treatments or those with heavily genericized indications, HEOR studies within specific patient populations deliver the comparative evidence required to support a product's refined value proposition.

Read More

Create economic models

Don't make price a barrier to patient access. Build effective account manager tools that demonstrate budget impact, cost-effectiveness, or disease burden.

Read More

Post-Launch: Additional Services

  • Expand All
  • Collapse All
  • Comparative Effectiveness ResearchMore

  • Prospective studiesMore

  • EpidemiologyMore

  • Stakeholder insightsMore

  • Risk managementMore

  • Global Value DossiersMore

  • TrainingMore

  • Health policy analysesMore

  • CompendiaMore

  • PAP strategyMore

  • Payer strategy and toolsMore

  • Value diagnosticMore

  • Contract HEOR staffMore

  • Contract field reimbursement specialistsMore

  • Provider educationMore